Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript

被引：0
|
作者：
A Tchirkov
J-L Couderc
B Périssel
C Goumy
A Regnier
N Uhrhammer
P Verrelle
M Berger
机构：
[1] Centre Jean Perrin,
[2] Service de Cytogénétique Médicale,undefined
[3] CHU – Faculté de Médecine,undefined
[4] UMR 384 INSERM,undefined
[5] Service de Médecine Interne,undefined
[6] CH,undefined
[7] Hématologie,undefined
[8] Faculté de Médecine,undefined
来源：
Leukemia | 2006年 / 20卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：167 / 168
页数：1
相关论文
共 50 条
  • [31] Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
    Barbosa Pagnano, Katia Borgia
    Miranda, Eliana Cristina
    Delamain, Marcia Torresan
    Duarte, Gislaine Oliveira
    de Paula, Erich Vinicius
    Lorand-Metze, Irene
    de Souza, Carmino Antonio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (11): : 728 - 733
  • [32] Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts
    Sharma, Pratibha
    Kumar, Lalit
    Mohanty, Sujata
    Kochupillai, Vinod
    ANNALS OF HEMATOLOGY, 2010, 89 (03) : 241 - 247
  • [33] BCR-ABL fusion gene and BCR-ABL transcript -: Correlation with response to therapy in Chronic Myeloid Leukaemia.
    Geraldes, C
    Gonçalves, AC
    Santos, P
    Tavares, P
    Teixeira, A
    BLOOD, 2005, 106 (11) : 297B - 297B
  • [34] Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts
    Pratibha Sharma
    Lalit Kumar
    Sujata Mohanty
    Vinod Kochupillai
    Annals of Hematology, 2010, 89 : 241 - 247
  • [35] Molecular deregulations mediated by Bcr-Abl in chronic myeloid leukemia
    Chomel, JC
    Guilhot, F
    Tanzer, J
    Kitzis, A
    M S-MEDECINE SCIENCES, 1995, 11 (12): : 1669 - 1678
  • [36] Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia
    Radich, Jerald P.
    CANCER, 2012, 118 (02) : 300 - 311
  • [37] Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript
    Lucas, Claire M.
    Harris, Robert J.
    Giannoudis, Athina
    Davies, Andrea
    Knight, Katy
    Watmough, Sarah J.
    Wang, Lihui
    Clark, Richard E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (10): : 1362 - 1367
  • [38] Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia
    Sun, Xiaoyan
    Cai, Xueting
    Yang, Jie
    Chen, Jiao
    Guo, Caixia
    Cao, Peng
    MOLECULES AND CELLS, 2016, 39 (12) : 869 - 876
  • [39] Chronic Myeloid Leukemia: Clinical Prestantation According to Bcr-Abl Transcript Variants
    Acosta Hernandez, Titania del Carmen
    Best Aguilera, Carlos Roberto
    Villela Martinez, Luis Mario
    Guzman Hernandez, Alicia Elizabeth
    Robles Rodriguez, Arianna
    Lopez Hernandez, Juan Carlos
    Gomez Vazquez, Oscar Rodrigo
    Rivera Mendoza, Laura Adriana
    Garcia Reyes, Barbara
    Gutierrez Alatorre, Aldo Fernando Adrian
    Calderon Valdez, Areli Sarai
    Visuetti Pimentel, Saribethe Mahely
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S243 - S243
  • [40] Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic mvelogenous leukemia
    Ishikawa, Izumi
    Kato, Chiaki
    Harigae, Hideo
    Sugawara, Tomohiro
    Tomiya, Yasuo
    Yamada, Minami
    Ishizawa, Kenichi
    Kameoka, Junichi
    Miyamura, Koichi
    Sasaki, Takeshi
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2006, 210 (04): : 355 - 363
12345